Exact Mass: 1022.5813856

Exact Mass Matches: 1022.5813856

Found 53 metabolites which its exact mass value is equals to given mass value 1022.5813856, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

CTX 3C

CTX 3C; Ciguatoxin CTX 3C; Ciguatoxin 3C

C57H82O16 (1022.5602572)


D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D002922 - Ciguatoxins

   

PGP(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-[(22-methyltetracosanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H92O16P2 (1022.5860292)


PGP(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 22-methyltetracosanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-25:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-[(22-methyltetracosanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H92O16P2 (1022.5860292)


PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-25:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-25:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 22-methyltetracosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PIP(22:3(10Z,13Z,16Z)/18:1(12Z)-O(9S,10R))

{[(1R,5S)-2,3,4,6-tetrahydroxy-5-({hydroxy[(2R)-2-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-3-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy]phosphoryl}oxy)cyclohexyl]oxy}phosphonic acid

C50H88O17P2 (1022.5496458000001)


PIP(22:3(10Z,13Z,16Z)/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:3(10Z,13Z,16Z)/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of 10Z,13Z,16Z-docosenoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(18:1(12Z)-O(9S,10R)/22:3(10Z,13Z,16Z))

{[(1R,5S)-2,3,4,6-tetrahydroxy-5-({hydroxy[(2R)-3-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-2-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy]phosphoryl}oxy)cyclohexyl]oxy}phosphonic acid

C50H88O17P2 (1022.5496458000001)


PIP(18:1(12Z)-O(9S,10R)/22:3(10Z,13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(18:1(12Z)-O(9S,10R)/22:3(10Z,13Z,16Z)), in particular, consists of one chain of 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 10Z,13Z,16Z-docosenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:3(10Z,13Z,16Z)/18:1(9Z)-O(12,13))

{[(1R,5S)-2,3,4,6-tetrahydroxy-5-({hydroxy[(2R)-2-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-3-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy]phosphoryl}oxy)cyclohexyl]oxy}phosphonic acid

C50H88O17P2 (1022.5496458000001)


PIP(22:3(10Z,13Z,16Z)/18:1(9Z)-O(12,13)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:3(10Z,13Z,16Z)/18:1(9Z)-O(12,13)), in particular, consists of one chain of 10Z,13Z,16Z-docosenoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(18:1(9Z)-O(12,13)/22:3(10Z,13Z,16Z))

{[(1R,5S)-2,3,4,6-tetrahydroxy-5-({hydroxy[(2R)-3-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-2-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy]phosphoryl}oxy)cyclohexyl]oxy}phosphonic acid

C50H88O17P2 (1022.5496458000001)


PIP(18:1(9Z)-O(12,13)/22:3(10Z,13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(18:1(9Z)-O(12,13)/22:3(10Z,13Z,16Z)), in particular, consists of one chain of 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 10Z,13Z,16Z-docosenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   
   
   
   
   
   
   

3-O-(2-O-beta-D-glucopyranosyl)-(6-O-methyl)-beta-D-glucuronopyranosyl-21,22-di-O-angeloy-R1-barrigenol

3-O-(2-O-beta-D-glucopyranosyl)-(6-O-methyl)-beta-D-glucuronopyranosyl-21,22-di-O-angeloy-R1-barrigenol

C53H82O19 (1022.5450022)


   

3beta-O-{alpha-L-arabinopyranosyl-(1->3)-beta-D-glucuronopyranosyl}-16alpha-acetoxy-21beta-{(Z)-2-methylbut-2-enoyloxy}-22alpha-(2-methylbutanoyloxy)-23,28-diihydroxyolean-12-ene|rogchaponin R9

3beta-O-{alpha-L-arabinopyranosyl-(1->3)-beta-D-glucuronopyranosyl}-16alpha-acetoxy-21beta-{(Z)-2-methylbut-2-enoyloxy}-22alpha-(2-methylbutanoyloxy)-23,28-diihydroxyolean-12-ene|rogchaponin R9

C53H82O19 (1022.5450022)


   
   

PIM1 36:3

2-O-(alpha-D-Manp)-(1-(9Z,12Z-octadecadienoyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1-myo-inositol)

C51H91O18P (1022.5942716)


   
   

PGP(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PGP(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C51H92O16P2 (1022.5860292)


   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-25:0)

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-25:0)

C51H92O16P2 (1022.5860292)


   

PIP(22:3(10Z,13Z,16Z)/18:1(12Z)-O(9S,10R))

PIP(22:3(10Z,13Z,16Z)/18:1(12Z)-O(9S,10R))

C50H88O17P2 (1022.5496458000001)


   

PIP(18:1(12Z)-O(9S,10R)/22:3(10Z,13Z,16Z))

PIP(18:1(12Z)-O(9S,10R)/22:3(10Z,13Z,16Z))

C50H88O17P2 (1022.5496458000001)


   

PIP(22:3(10Z,13Z,16Z)/18:1(9Z)-O(12,13))

PIP(22:3(10Z,13Z,16Z)/18:1(9Z)-O(12,13))

C50H88O17P2 (1022.5496458000001)


   

PIP(18:1(9Z)-O(12,13)/22:3(10Z,13Z,16Z))

PIP(18:1(9Z)-O(12,13)/22:3(10Z,13Z,16Z))

C50H88O17P2 (1022.5496458000001)


   

ciguatoxin CTX3C

ciguatoxin CTX3C

C57H82O16 (1022.5602572)


A ciguatoxin comprising a sequence of twelve trans-fused six-, seven-, eight- and nine-membered oxacycles and a spiro-fused tetrahydrofuran. D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D002922 - Ciguatoxins

   
   
   
   
   

[1-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate

[1-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate

C59H91O12P (1022.6247816)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate

C59H91O12P (1022.6247816)


   
   
   

PIM1(18:2(9Z,12Z)/18:1(9Z))

PIM1(18:2(9Z,12Z)/18:1(9Z))

C51H91O18P (1022.5942716)


   
   
   

Fibronectin Adhesion-promoting Peptide

Fibronectin Adhesion-promoting Peptide

C47H74N16O10 (1022.5773544)


Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells[1][2].

   

n-{4-[4-(3-{2-[(13e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl}prop-1-en-1-yl)-1,3-oxazol-2-yl]pentan-2-yl}-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

n-{4-[4-(3-{2-[(13e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl}prop-1-en-1-yl)-1,3-oxazol-2-yl]pentan-2-yl}-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

C51H83N4O15P (1022.5592257999999)


   

methyl (2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,7r,8s,8ar,9r,10r,12as,14ar,14br)-7,8-dihydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-9,10-bis({[(2z)-2-methylbut-2-enoyl]oxy})-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

methyl (2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,7r,8s,8ar,9r,10r,12as,14ar,14br)-7,8-dihydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-9,10-bis({[(2z)-2-methylbut-2-enoyl]oxy})-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

C53H82O19 (1022.5450022)


   

2-{[(2-{2-[2-(1-{2-[2-({2-[6-(4,6-dimethyl-5-oxoocta-2,6-dien-2-yl)-2-hydroxy-5-methyloxan-2-yl]-1,2-dihydroxypropylidene}amino)-3-hydroxy-4-methylpentanoyl]-1,2-diazinan-3-yl}-n-hydroxyformamido)-n-methylpropanamido]-4-methylpentanoyl}-1,2-diazinan-3-yl)(hydroxy)methylidene]amino}-3-hydroxybutanoic acid

2-{[(2-{2-[2-(1-{2-[2-({2-[6-(4,6-dimethyl-5-oxoocta-2,6-dien-2-yl)-2-hydroxy-5-methyloxan-2-yl]-1,2-dihydroxypropylidene}amino)-3-hydroxy-4-methylpentanoyl]-1,2-diazinan-3-yl}-n-hydroxyformamido)-n-methylpropanamido]-4-methylpentanoyl}-1,2-diazinan-3-yl)(hydroxy)methylidene]amino}-3-hydroxybutanoic acid

C49H82N8O15 (1022.5899342)


   

2-methyl-5-[(2-methylbutanoyl)oxy]-6-({4,5,24,25-tetrahydroxy-6-methyl-20-oxo-10-pentyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-26-yl}oxy)-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl 2-methylbutanoate

2-methyl-5-[(2-methylbutanoyl)oxy]-6-({4,5,24,25-tetrahydroxy-6-methyl-20-oxo-10-pentyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-26-yl}oxy)-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl 2-methylbutanoate

C50H86O21 (1022.5661306)


   

(1s,3as,3br,7s,9ar,9bs,11r,11as)-1-acetyl-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-2-methylbut-2-enoate

(1s,3as,3br,7s,9ar,9bs,11r,11as)-1-acetyl-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-2-methylbut-2-enoate

C54H86O18 (1022.5813856)


   

(2s,3s,4r,5r,6s)-2-methyl-5-{[(2s)-2-methylbutanoyl]oxy}-6-{[(1s,3r,4s,5r,6r,8r,10s,23r,24s,25s,26r)-4,5,24,25-tetrahydroxy-6-methyl-20-oxo-10-pentyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-26-yl]oxy}-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2s)-2-methylbutanoate

(2s,3s,4r,5r,6s)-2-methyl-5-{[(2s)-2-methylbutanoyl]oxy}-6-{[(1s,3r,4s,5r,6r,8r,10s,23r,24s,25s,26r)-4,5,24,25-tetrahydroxy-6-methyl-20-oxo-10-pentyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-26-yl]oxy}-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2s)-2-methylbutanoate

C50H86O21 (1022.5661306)


   

(2r,3r,4r)-n-[(2r,4s)-4-{4-[(1e)-3-[(2r,3r,5r,7s,8s,9r)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl]prop-1-en-1-yl]-1,3-oxazol-2-yl}pentan-2-yl]-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

(2r,3r,4r)-n-[(2r,4s)-4-{4-[(1e)-3-[(2r,3r,5r,7s,8s,9r)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl]prop-1-en-1-yl]-1,3-oxazol-2-yl}pentan-2-yl]-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

C51H83N4O15P (1022.5592257999999)


   

n-{4-[4-(3-{2-[(11e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl}prop-1-en-1-yl)-1,3-oxazol-2-yl]pentan-2-yl}-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

n-{4-[4-(3-{2-[(11e)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl]-9-hydroxy-4,4,8-trimethyl-3-(phosphonooxy)-1,6-dioxaspiro[4.5]decan-7-yl}prop-1-en-1-yl)-1,3-oxazol-2-yl]pentan-2-yl}-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanimidic acid

C51H83N4O15P (1022.5592257999999)


   

(5r,8s,11r,15s,18s,19s,22r)-18-[(1e,3e,5s,6s)-6-(acetyloxy)-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-15-(4-carbamimidamidobutyl)-3,6,9,13,16,20-hexahydroxy-1,5,19-trimethyl-2-methylidene-8-(2-methylpropyl)-25-oxo-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid

(5r,8s,11r,15s,18s,19s,22r)-18-[(1e,3e,5s,6s)-6-(acetyloxy)-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-15-(4-carbamimidamidobutyl)-3,6,9,13,16,20-hexahydroxy-1,5,19-trimethyl-2-methylidene-8-(2-methylpropyl)-25-oxo-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid

C50H74N10O13 (1022.5436554)


   

(1s,3as,3br,7s,9ar,9bs,11r,11as)-1-acetyl-3a-hydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,3r,4r,5r,6r)-3-hydroxy-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-2-methylbut-2-enoate

(1s,3as,3br,7s,9ar,9bs,11r,11as)-1-acetyl-3a-hydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,3r,4r,5r,6r)-3-hydroxy-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-2-methylbut-2-enoate

C54H86O18 (1022.5813856)